Document Detail


Pre-emptive conditioning of the ischemic heart.
MedLine Citation:
PMID:  18473774     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ischemic heart disease remains one of the most frequent causes of morbidity and mortality worldwide. Although the prognosis of myocardial ischemia has been dramatically improved by the techniques of early reperfusion, the prevention of irreversible ischemic damage remains a critical aspect of the treatment. An appealing novel therapeutic avenue for the prevention of myocardial ischemia relates to the possibility of a pre-emptive conditioning of the heart, in which an activation of survival pathways could be achieved in patients with ischemic heart disease who are at risk for a subsequent lethal ischemia. These patients would include those with unstable angina, or with severe and repetitive ischemic episodes, and patients scheduled for surgical revascularization. In these situations, the pre-emptive activation of survival signaling mechanisms would confer a prophylactic cardioprotection during the following ischemic stress. During the last twenty years, it became clear that the heart can trigger survival mechanisms when submitted to stress, in such conditions as myocardial stunning, hibernation and preconditioning. The goal of the pre-emptive conditioning is to activate such survival pathways as a prophylactic measure to prevent myocardial cell death when the heart is threatened by potentially lethal ischemia. Based on the experimental data collected at the bench side, we review how this approach could be applied in the clinical setting.
Authors:
Joseph M Vitale; Hongyu Qiu; Christophe Depre
Related Documents :
11491204 - Clinical importance of stunned and hibernating myocardium.
17522584 - The fibrin-derived peptide bbeta15-42 is cardioprotective in a pig model of myocardial ...
18946174 - Attenuation of cardioprotective effect by postconditioning in coronary stenosed rat hea...
8400024 - The influence of the time period between preconditioning ischemia and prolonged ischemi...
10333034 - Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenou...
1355284 - Treatment of vasospasm by balloon angioplasty: experimental studies and clinical experi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular & hematological agents in medicinal chemistry     Volume:  6     ISSN:  1871-5257     ISO Abbreviation:  -     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-05-13     Completed Date:  2008-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101266881     Medline TA:  Cardiovasc Hematol Agents Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  92-104     Citation Subset:  IM    
Affiliation:
Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, 185 South Orange Street, MSB G-609, Newark, NJ 07103, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Humans
Ischemic Preconditioning, Myocardial* / methods
Myocardial Ischemia / physiopathology,  prevention & control*,  therapy
Myocardial Stunning / physiopathology
Risk Factors
Survival Rate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Non peptidic urotensin II antagonists: perspectives for a new class of drugs.
Next Document:  Drug-eluting stents: present and future.